Business Context and Reporting Period
Company: AN2 Therapeutics, Inc. (ANTX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2026
Reporting Period: Event-based report regarding clinical and preclinical study results announced on June 4, 2026.
Key Financial Metrics
This filing is a Current Report on Form 8-K focused on regulatory and scientific developments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Key Developments
The Company announced positive results from two studies evaluating its oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease:
- 28-Day Nonhuman Primate (NHP) Study:
- 100% of treated macaques with naturally-acquired chronic T. cruzi infection achieved parasite elimination at target exposures attainable in humans.
- Elimination of parasitemia was durable, maintained through four months post-treatment.
- The compound was well tolerated with no drug-related adverse events.
- AN2-502998 is the only compound to demonstrate curative activity in NHPs with long-term, naturally acquired T. cruzi infection.
- Phase 1 First-in-Human (FIH) Study (NCT07024589):
- Evaluated single and multiple ascending oral doses in healthy adult volunteers.
- The drug was generally well tolerated with no dose-limiting toxicities.
- Human pharmacokinetics (PK) were well characterized, achieving plasma exposures at or above NHP efficacy thresholds.
Outlook, Management Commentary, and Risks
Market Opportunity: The Company views Chagas disease as a potential multi-billion-dollar global market, citing an estimated 300,000 infected individuals in the U.S., 200,000 in Europe and Japan, and 10 million worldwide. There are currently no FDA-approved treatments for adults with Chagas disease.
Strategic Initiatives:
- AN2 is collaborating with the Drugs for Neglected Diseases initiative (DNDi) to ensure global access in endemic developing regions.
- If approved, AN2-502998 would be eligible for an FDA Tropical Disease Priority Review Voucher.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Key risks include the ability of NHP models to predict human efficacy, clinical trial enrollment, supply procurement, potential adverse events, regulatory approval uncertainty, intellectual property protection, and the sufficiency of capital resources.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data on the NHP and Phase 1 studies.
- Confirm the timeline for the initiation of Phase 2 clinical trials and the status of the collaboration with DNDi.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and capital requirements, as this 8-K does not provide financial data.
- Assess the regulatory pathway and specific criteria for the FDA Tropical Disease Priority Review Voucher.
- Monitor for any updates on the supply chain capabilities for AN2-502998 to support future clinical phases.